{"id":78527,"date":"2026-09-03T17:29:15","date_gmt":"2026-09-03T09:29:15","guid":{"rendered":"https:\/\/flcube.com\/?p=78527"},"modified":"2026-09-03T17:29:16","modified_gmt":"2026-09-03T09:29:16","slug":"cutia-therapeutics-cu-20101-bla-accepted-by-nmpa-for-moderate-to-severe-glabellar-lines-advancing-a-safer-botulinum-toxin-type-a","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=78527","title":{"rendered":"Cutia Therapeutics’ CU\u201120101 BLA Accepted by NMPA for Moderate to Severe Glabellar Lines, Advancing a Safer Botulinum Toxin Type A"},"content":{"rendered":"\n

Cutia Therapeutics<\/strong> (HKG: 2487<\/a>) announced that the Biologics License Application (BLA) for CU\u201120101<\/strong> has been accepted by the National Medical Products Administration (NMPA)<\/strong> of China for the indication of improving moderate to severe glabellar lines. The filing positions CU\u201120101<\/strong> \u2014 a botulinum toxin type A for injection manufactured without animal\u2011derived materials or human serum albumin \u2014 as a differentiated, safety\u2011oriented entrant in China’s fast\u2011growing neurotoxin aesthetics market.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Agency<\/td>National Medical Products Administration (NMPA)<\/strong>, China<\/td><\/tr>
Application Type<\/td>Biologics License Application (BLA), accepted<\/td><\/tr>
Product<\/td>CU\u201120101<\/strong>, botulinum toxin type A for injection<\/td><\/tr>
Indication<\/td>Improvement of moderate to severe glabellar lines<\/td><\/tr>
Applicant<\/td>Cutia Therapeutics<\/strong> (HKG: 2487)<\/td><\/tr>
Next Steps<\/td>Regulatory review toward potential approval and commercial launch<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile & Differentiation<\/h2>\n\n\n\n